Evaluating adverse events reported for non-steroidal anti-inflammatory drugs in osteoarthritis: a real-world pharmacovigilance study.

No abstract is available for this paper.

• Publication year

  2026

• Venue

  InflammoPharmacology

• Publication date

  2026-02-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10787-026-02129-1PMID 41656471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Exploring the potential association between stimulant or atomoxetine use and suicidal or self-injurious behaviors in children with attention deficit hyperactivity disorder: real-world insights from the FAERS database

  2025cited by this paper
• Correction: Charting and Sidestepping the Pitfalls of Disproportionality Analysis

  2025cited by this paper
• Pharmacovigilance study of drug-induced eye movement disorder based on FDA adverse event reports from 2004 to 2024

  2025cited by this paper
• Uncovering safety signals of duloxetine: Real-world evidence from the FAERS database.

  2025cited by this paper
• Gastrointestinal adverse events associated with SNRIs: A FAERS-based pharmacovigilance study.

  2025cited by this paper
• FDA Adverse Event Reporting System (FAERS) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS

  2025cited by this paper
• Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database

  2025cited by this paper
• Advances and Challenges in the Pursuit of Disease-Modifying Osteoarthritis Drugs: A Review of 2010–2024 Clinical Trials

  2025cited by this paper
• Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database

  2025cited by this paper
• Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database

  2025cited by this paper
• The Risk of Propofol Infusion Syndrome on Epilepsy Patients :Insights from FAERS Data and Published Case Reports.

  2025cited by this paper
• Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis

  2024cited by this paper
• The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement

  2024cited by this paper
• Clinical investigation for the mechanisms of anaphylactic symptoms in osteoarthritis patients after diclofenac etalhyaluronate administration.

  2023cited by this paper
• Diacerein versus non-steroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: a meta-analysis

  2023cited by this paper
• Translating osteoarthritis genetics research: challenging times ahead.

  2022cited by this paper
• Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source

  2021cited by this paper
• Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis

  2021cited by this paper
• Topical Diclofenac, an Efficacious Treatment for Osteoarthritis: A Narrative Review

  2020cited by this paper
• Syndrome of Inappropriate Antidiuretic Hormone (SIADH) Induced by Long-Term Use of Citalopram and Short-Term Use of Naproxen

  2020cited by this paper
• Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis

  2019cited by this paper
• Ibuprofen Safety at the Golden Anniversary: Are all NSAIDs the Same? A Narrative Review

  2019cited by this paper
• Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis

  2019cited by this paper
• Celecoxib for osteoarthritis.

  2017cited by this paper
• Oral Versus Topical Diclofenac Sodium in the Treatment of Osteoarthritis

  2017cited by this paper
• Prevalence of depressive symptoms and anxiety in osteoarthritis: a systematic review and meta-analysis.

  2016cited by this paper
• Good Signal Detection Practices: Evidence from IMI PROTECT

  2016cited by this paper
• Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis

  2015cited by this paper
• Risk of Upper Gastrointestinal Ulcers in Patients With Osteoarthritis Receiving Single-Tablet Ibuprofen/Famotidine Versus Ibuprofen Alone: Pooled Efficacy and Safety Analyses of Two Randomized, Double-Blind, Comparison Trials

  2014cited by this paper
• Osteoarthritis Pathogenesis: A Review of Molecular Mechanisms

  2014cited by this paper
• Illustration of the Weibull Shape Parameter Signal Detection Tool Using Electronic Healthcare Record Data

  2013cited by this paper
• Epidemiology and burden of osteoarthritis.

  2013cited by this paper
• Syndrome of Inappropriate Antidiuretic Hormone Secretion and Ibuprofen, a Rare Association to Be Considered: Role of Tolvaptan

  2013cited by this paper
• Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

  2013cited by this paper
• Osteoarthritis of the knee and hip. Part II: therapy with ibuprofen and a review of clinical trials

  2012cited by this paper
• Epidemiology of Osteoarthritis and Associated Comorbidities

  2012cited by this paper
• Modelling Therapeutic Strategies in the Treatment of Osteoarthritis

  2012cited by this paper
• NSAIDs and Acidic Environment Induce Gastric Mucosal Cellular Mitochondrial Dysfunction

  2012cited by this paper
• Rofecoxib

  2012cited by this paper
• Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers

  2011cited by this paper
• Reciprocal relationship between pain and depression: a 12-month longitudinal analysis in primary care.

  2011cited by this paper
• Clinical trial: the incidence of NSAID‐associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric‐coated naproxen alone

  2010cited by this paper
• Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?

  2008cited by this paper
• Risk of myocardial infarction associated with selective COX‐2 inhibitors: Meta‐analysis of randomised controlled trials

  2007cited by this paper
• Effect of the COX-2 Inhibitor Celecoxib on Behavioural and Immune Changes in an Olfactory Bulbectomised Rat Model of Depression

  2007cited by this paper
• Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib

  2007cited by this paper
• Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.

  2007cited by this paper
• A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis.

  2007cited by this paper
• Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs.

  2006cited by this paper
• Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.

  2006cited by this paper
• Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.

  2006cited by this paper
• Non-steroidal anti-inflammatory drug (NSAID)-induced colonic strictures and perforation: a case report.

  2006cited by this paper
• The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

  2006cited by this paper
• Osteoarthritis

  2006cited by this paper
• Rofecoxib for osteoarthritis.

  2005cited by this paper
• Visible small-intestinal mucosal injury in chronic NSAID users.

  2005cited by this paper
• Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial.

  2005cited by this paper
• Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis

  2004cited by this paper
• A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis

  2004cited by this paper
• Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.

  2001cited by this paper
• Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.

  2001cited by this paper
• Endoscopic Comparison of the Gastroduodenal Safety and the Effects on Arachidonic Acid Products between Meloxicam and Piroxicam in the Treatment of Osteoarthritis

  2001cited by this paper
• Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study.

  1998cited by this paper

• NSAID-related AEs in patients with osteoarthritis

  2026cites this paper